Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: LGND stock price vs REPL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REPL's multiple
Needs REPL P/E.
Implied fair value · at LGND's multiple
Needs EPS (TTM) is negative, LGND P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · REPL FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
REPLIMUNE GROUP, INC. · implied price per share
Cash flow and years must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
0.60x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$268.89M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$252.03M
$83.31M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND can sustain its 60.4% revenue growth and high margins while the market continues to reward quality, then holding or accumulating on pullbacks makes sense because the balance sheet is strong and profitability is real; if not, the DCF range suggests the current price already discounts a lot of optimism.
LGND trades at a premium valuation on both earnings and sales, with a P/E of 41.5x and P/S of 19.0x, while REPL's negative earnings make direct multiple comparison less informative. The current price of $254.57 sits near the top of LGND's historical band of $229.11 to $280.03, but well above the DCF range of $80.49 to $108.90.
Supporting Metrics
Live quote
